By Sherri Oslick —

A
note to our readers:  In an effort to catch up with recently filed
biotech and pharma cases following a brief hiatus, Patent Docs presents this additional installment of Court Report.

Teva Women's Health, Inc. v. Lupin, Ltd. et al.
2:10-cv-00603; filed February 3, 2010 in the
District Court of New Jersey

• Plaintiff:  Teva Women's Health, Inc.
• Defendants:  Lupin, Ltd.; Lupin Pharmaceuticals, Inc.

Infringement of U.S. Patent No. 7,320,969 ("Oral
Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology,"
issued January 22, 2008) following a Paragraph IV certification as part of Lupin's
filing of an ANDA to manufacture a generic version of Teva Women's Health's
(formerly Duramed) Seasonique® (levonorgestrel/ethinyl estradiol, used as oral
contraception).  View the complaint here.

Sepracor, Inc. v. Teva Parenteral Medicines, Inc. et al.
1:10-cv-00746; filed February 1, 2010 in the
Southern District of New York

• Plaintiff:  Sepracor, Inc.
• Defendants:  Teva Parenteral Medicines, Inc.; Teva Pharmaceuticals USA,
Inc.; Teva Pharmaceutical Industries, Ltd.

Infringement of U.S. Patent Nos. 6,472,563 ("Formoterol
Tartrate Process and Plymorph," issued October 29, 2002), 6,720,453 ("Formoterol
Tartrate Polymorph," issued April 13, 2004), and 7,145,036 (same title,
issued December 5, 2006) following a Paragraph IV certification as part of Teva's
filing of an ANDA to manufacture a generic version of Sepracor's Brovana®
(arformoterol tartrate, used to treat bronchoconstriction in patients with chronic
obstructive pulmonary disease).  View the complaint here.

Endo Pharmaceuticals Inc. et al. v. Roxane Laboratories, Inc.
2:10-cv-00534; filed January 29, 2010 in the
District Court of New Jersey

• Plaintiffs:  Endo Pharmaceuticals Inc.; Penwest Pharmaceuticals Co.
• Defendant:  Roxane Laboratories, Inc.

Infringement of U.S. Patent No. 5,958,456 ("Controlled
Release Formulation (Albuterol)," issued September 28, 1999) following a
Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture
a generic version of Endo's Opana® ER (oxymorphone hydrochloride, used to treat
moderate to severe pain in patients requiring continuous, around-the-clock
opioid treatment for an extended period of time).  View the complaint here.

Warner Chilcott Co., LLC et al. v. Sandoz Inc.
2:10-cv-00511; filed January 28, 2010 in the
District Court of New Jersey

• Plaintiffs:  Warner Chilcott Co., LLC; Warner Chilcott (US), LLC; Mayne
Pharma International Pty. Ltd.
• Defendant:  Sandoz Inc.

Infringement of U.S. Patent No. 6,958,161 ("Modified
Release Coated Drug Preparation," issued October 25, 2005) following a
Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture
a generic version of Warner Chilcott's Doryx® (modified release doxycycline
hyclate, used to treat a variety of bacterial infections).  View the complaint here.